利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

155 条记录 (耗时 0.048 秒)

    Antibodies to Carcinoembryonic Antigen (CEA), Methods of Making Same, and Uses Thereof
    44.
    发明申请
    Antibodies to Carcinoembryonic Antigen (CEA), Methods of Making Same, and Uses Thereof 审中-公开
    癌胚抗原抗体（CEA），制备方法及用途

    公开(公告)号：US20160075795A1

    公开(公告)日：2016-03-17

    申请号：US14721795

    申请日：2015-05-26

    申请人： Roche GlycArt AG

    发明人： Ekkehard MÖSSNER ,  Thomas U. Hofer ,  Ralf Jörg Hosse ,  Pablo Umana

    IPC分类号： C07K16/30

    CPC分类号： C07K16/3007 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/92

    摘要： The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies or variants thereof specific for cell surface or membrane bound human CEA. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.

    摘要翻译： 本发明涉及抗原结合分子（ABM）。 在具体实施方案中，本发明涉及重组单克隆抗体，包括特异于细胞表面或膜结合人CEA的嵌合，灵长类或人源化抗体或其变体。 此外，本发明涉及编码这种ABM的核酸分子以及包含该核酸分子的载体和宿主细胞。 本发明还涉及生产本发明的ABM的方法以及使用这些ABM在治疗疾病中的方法。 此外，本发明涉及具有改善的治疗性质的具有改性糖基化的ABM，包括具有增加的Fc受体结合和增加的效应子功能的抗体。

    COMBINATION THERAPY WITH TYPE I AND TYPE II ANTI-CD20 ANTIBODIES
    49.
    发明申请
    COMBINATION THERAPY WITH TYPE I AND TYPE II ANTI-CD20 ANTIBODIES 审中-公开
    与I型和II型抗CD20抗体的联合治疗

    公开(公告)号：US20140294807A1

    公开(公告)日：2014-10-02

    申请号：US14067799

    申请日：2013-10-30

    申请人： ROCHE GLYCART AG

    发明人： THOMAS FRIESS ,  CHRISTIAN KLEIN ,  PABLO UMANA

    IPC分类号： A61K39/395

    CPC分类号： A61K39/39558 ,  A61K2039/507 ,  C07K16/2887 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/56

    摘要： The present invention is directed to a combination therapy involving a type I anti-CD20 antibody and a type II anti-CD20 antibody for the treatment of a patient suffering from cancer, particularly a CD20-expressing cancer. An aspect of the invention is a composition comprising a type I anti-CD20 antibody and a type II anti-CD20 antibody. Another aspect of the invention is a kit comprising a type I anti-CD20 antibody and a type II anti-CD20 antibody. Yet another aspect of the invention is a method for the treatment of a patient suffering from cancer comprising co-administering, to a patient in need of such treatment, a type I anti-CD20 antibody and a type II anti-CD20 antibody.

    摘要翻译： 本发明涉及涉及用于治疗患有癌症的患者，特别是CD20表达癌症的患者的I型抗CD20抗体和II型抗-CD20抗体的组合疗法。 本发明的一个方面是包含I型抗CD20抗体和II型抗-CD20抗体的组合物。 本发明的另一方面是包含I型抗CD20抗体和II型抗CD20抗体的试剂盒。 本发明的另一方面是用于治疗患有癌症的患者的方法，包括向需要这种治疗的患者共同给予I型抗CD20抗体和II型抗-CD20抗体。